By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Biological Factors. According to news originating from Tehran, Iran, by NewsRx correspondents, research stated, "We report on a competitive immunoassay for the determination of aflatoxin B1 using fluorescence resonance energy transfer (FRET) from anti-aflatoxin B1 antibody (immobilized on the shell of CdTe quantum dots) to Rhodamine 123 (Rho 123-labeled aflatoxin B1 bound to albumin). The highly specific immunoreaction between the antibody against aflatoxin B1 on the QDs and the labeled-aflatoxin B1 brings the Rho 123 fluorophore (acting as the acceptor) and the QDs (acting as the donor) in close spatial proximity and causes FRET to occur upon photoexcitation of the QDs."
Our news journalists obtained a quote from the research from the Department of Research & Development, "In the absence of unlabeled aflatoxin B1, the antigen-antibody complex is stable, and strong emission resulting from the FRET from QDs to labeled aflatoxin B1 is observed. In the presence of aflatoxin B1, it will compete with the labeled aflatoxin B1-albumin complex for binding to the antibody-QDs conjugate so that FRET will be increasingly suppressed. The reduction in the fluorescence intensity of the acceptor correlates well with the concentration of aflatoxin B1. The feasibility of the method was established by the detection of aflatoxin B1 in spiked human serum. There is a linear relationship between the increased fluorescence intensity of Rho 123 with increasing concentration of aflatoxin B1 in spike human serum, over the range of 0.1-0.6 mu mol center dot mL(-1)."
According to the news editors, the research concluded: "The limit of detection is 2 x 10(-11) M. This homogeneous competitive detection scheme is simple, rapid and efficient, and does not require excessive washing and separation steps."
For more information on this research see: Highly sensitive FRET-based fluorescence immunoassay for aflatoxin B1 using cadmium telluride quantum dots. Microchimica Acta, 2013;180(13-14):1217-1223. Microchimica Acta can be contacted at: Springer Wien, Sachsenplatz 4-6, PO Box 89, A-1201 Wien, Austria. (Springer - www.springer.com; Microchimica Acta - www.springerlink.com/content/0026-3672/)
The news correspondents report that additional information may be obtained from R. Zekavati, Nanozino, Dept. of Res & Dev, Tehran, Iran. Additional authors for this research include S. Safi, S.J. Hashemi, T. Rahmani-Cherati, M. Tabatabaei, A. Mohsenifar and M. Bayat (see also Biological Factors).
Keywords for this news article include: Iran, Asia, Antibodies, Tehran, Chemicals, Chemistry, Aflatoxins, Immunology, Mycotoxins, Quantum Dots, Blood Proteins, Nanotechnology, Immunoglobulins, Quantum Physics, Cadmium Telluride, Biological Factors, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC